Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care

Benzinga recently spoke to the CEO of BioStem Technologies, Inc. BSEM (“BioStem”), Jason Matuszewski, about his company’s mission and future. 

BioStem is a leading biotech innovator focused on harnessing the natural properties of perinatal tissue to help patients with advanced wound care. The company has created the BioRetain® method to advance the development, manufacture, and commercialization of allografts for regenerative therapies. 

BioRetain has been able to successfully preserve the tissue's natural endogenous biological properties while maintaining the structure and matrix found in fresh perinatal tissue. This makes it an ideal therapy for millions of Americans. 

Matuszewski explained that there is no shortage of demand for better and new allograft technology. He explained that much of the company’s target audience is made up of individuals over the age of 65 and diabetics; both populations have impaired healing abilities. When a patient experiences impaired healing, they are more likely to suffer from chronic wounds or non-healing wounds. These wounds, if left untreated, can result in infections and even amputations. 

Approximately 3-6 million people in the US suffer from chronic wounds. One of the most dangerous, prevalent, and costly chronic wounds is diabetic foot ulcer (DFU). 15% of people with DFU require at least one major amputation in their lifetime. BioStem has worked with Saving Limbs, Saving Lives to prevent amputations. 

Matuszewski shared that BioStem recently announced its partnership with Kill Cliff Fight Club (“Kill Cliff FC”), a world-renowned MMA training center located in Southern Florida. The center has more than 80 professional Mixed Martial Artists.

MMA athletes are subject to a lot of trauma and acute wounds that can impact their professional life. Matuszewski explained that BioStem is able to provide care, limit scar tissue, and heal them so they can continue their career safely. BioStem recently provided treatment to Gregory Rodrigues after he sustained a serious cut on his forehead. BioStem’s regenerative therapies allow athletes to focus less on their injuries and more on returning to the ring and performing at optimal levels.

Matuszewski also mentioned that the company saw a 15% year-on-year increase in gross profit in Q3 of 2022, up from 2021. He expects the company to continue to grow and expand in 2023 and sees a lot of opportunity in the advanced wound care market that BioStem looks to dominate.

Watch the full video here:

 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured Photo by Mikita Yo on Unsplash